CTLA4 and neoplasm: As previously described, the immune checkpoint molecules PD-L1 and CTLA-4 are overexpressed by dormant tumor cells, enabling them to evade immune surveillance.30,55 This observation has prompted the proposal that immune checkpoint inhibitors may be employed to amplify T-cell-mediated elimination of dormant tumor populations, thereby reducing recurrence rates and improving clinical outcomes.